186 related articles for article (PubMed ID: 38165708)
1. GATA-3-dependent Gene Transcription is Impaired upon HDAC Inhibition.
Geng X; Wang C; Abdelrahman S; Perera T; Saed B; Hu YS; Wolfe A; Reneau J; Murga-Zamalloa C; Wilcox RA
Clin Cancer Res; 2024 Mar; 30(5):1054-1066. PubMed ID: 38165708
[TBL] [Abstract][Full Text] [Related]
2. Novel cell adhesion/migration pathways are predictive markers of HDAC inhibitor resistance in cutaneous T cell lymphoma.
Andrews JM; Schmidt JA; Carson KR; Musiek AC; Mehta-Shah N; Payton JE
EBioMedicine; 2019 Aug; 46():170-183. PubMed ID: 31358475
[TBL] [Abstract][Full Text] [Related]
3. Current Status of HDAC Inhibitors in Cutaneous T-cell Lymphoma.
Lopez AT; Bates S; Geskin L
Am J Clin Dermatol; 2018 Dec; 19(6):805-819. PubMed ID: 30173294
[TBL] [Abstract][Full Text] [Related]
4. Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL.
Rozati S; Cheng PF; Widmer DS; Fujii K; Levesque MP; Dummer R
Clin Cancer Res; 2016 Apr; 22(8):2020-31. PubMed ID: 26660520
[TBL] [Abstract][Full Text] [Related]
5. Combination of retinoid and histone deacetylase inhibitor produced an anti-tumor effect in cutaneous T-cell lymphoma by restoring tumor suppressor gene, retinoic acid receptorβ2, via histone acetylation.
Kato Y; Egusa C; Maeda T; Tsuboi R
J Dermatol Sci; 2016 Jan; 81(1):17-25. PubMed ID: 26596218
[TBL] [Abstract][Full Text] [Related]
6. Chromatin Accessibility Landscape of Cutaneous T Cell Lymphoma and Dynamic Response to HDAC Inhibitors.
Qu K; Zaba LC; Satpathy AT; Giresi PG; Li R; Jin Y; Armstrong R; Jin C; Schmitt N; Rahbar Z; Ueno H; Greenleaf WJ; Kim YH; Chang HY
Cancer Cell; 2017 Jul; 32(1):27-41.e4. PubMed ID: 28625481
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.
Abe F; Kitadate A; Ikeda S; Yamashita J; Nakanishi H; Takahashi N; Asaka C; Teshima K; Miyagaki T; Sugaya M; Tagawa H
Oncotarget; 2017 Jan; 8(5):7572-7585. PubMed ID: 27935859
[TBL] [Abstract][Full Text] [Related]
8. BCL11B-Mediated Epigenetic Repression Is a Crucial Target for Histone Deacetylase Inhibitors in Cutaneous T-Cell Lymphoma.
Fu W; Yi S; Qiu L; Sun J; Tu P; Wang Y
J Invest Dermatol; 2017 Jul; 137(7):1523-1532. PubMed ID: 28288848
[TBL] [Abstract][Full Text] [Related]
9. Mass spectrometry and DigiWest technology emphasize protein acetylation profile from Quisinostat-treated HuT78 CTCL cell line.
Méhul B; Perrin A; Grisendi K; Galindo AN; Dayon L; Ménigot C; Rival Y; Voegel JJ
J Proteomics; 2018 Sep; 187():126-143. PubMed ID: 30012418
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitors potentiate photochemotherapy in cutaneous T-cell lymphoma MyLa cells.
Sung JJ; Ververis K; Karagiannis TC
J Photochem Photobiol B; 2014 Feb; 131():104-12. PubMed ID: 24518645
[TBL] [Abstract][Full Text] [Related]
11. Preclinical Studies Support Combined Inhibition of BET Family Proteins and Histone Deacetylases as Epigenetic Therapy for Cutaneous T-Cell Lymphoma.
Zhao L; Okhovat JP; Hong EK; Kim YH; Wood GS
Neoplasia; 2019 Jan; 21(1):82-92. PubMed ID: 30529073
[TBL] [Abstract][Full Text] [Related]
12. Involvement of p53 Acetylation in Growth Suppression of Cutaneous T-Cell Lymphomas Induced by HDAC Inhibition.
Yu X; Li H; Zhu M; Hu P; Liu X; Qing Y; Wang X; Wang H; Wang Z; Xu J; Tan R; Guo Q; Hui H
J Invest Dermatol; 2020 Oct; 140(10):2009-2022.e4. PubMed ID: 32119867
[TBL] [Abstract][Full Text] [Related]
13. A single center phase II study of ixazomib in patients with relapsed or refractory cutaneous or peripheral T-cell lymphomas.
Boonstra PS; Polk A; Brown N; Hristov AC; Bailey NG; Kaminski MS; Phillips T; Devata S; Mayer T; Wilcox RA
Am J Hematol; 2017 Dec; 92(12):1287-1294. PubMed ID: 28842936
[TBL] [Abstract][Full Text] [Related]
14. The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells.
Tiffon C; Adams J; van der Fits L; Wen S; Townsend P; Ganesan A; Hodges E; Vermeer M; Packham G
Br J Pharmacol; 2011 Apr; 162(7):1590-602. PubMed ID: 21198545
[TBL] [Abstract][Full Text] [Related]
15. Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients.
Cyrenne BM; Lewis JM; Weed JG; Carlson KR; Mirza FN; Foss FM; Girardi M
Blood; 2017 Nov; 130(19):2073-2083. PubMed ID: 28972015
[TBL] [Abstract][Full Text] [Related]
16. Cellular Gene Modulation of HIV-Infected CD4 T Cells in Response to Serial Treatment with the Histone Deacetylase Inhibitor Vorinostat.
Maxwell JW; Falcinelli SD; Nefedov A; Dorfmeier C; Wu G; Dewey M; Webber AL; Archin NM; Margolis DM; Hazuda DJ; Barnard RJO; Howell BJ
J Virol; 2020 Jun; 94(13):. PubMed ID: 32295913
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological characterization of histone deacetylase inhibitor and tumor cell-growth inhibition properties of new benzofuranone compounds.
Blanquart C; François M; Charrier C; Bertrand P; Gregoire M
Curr Cancer Drug Targets; 2011 Oct; 11(8):919-28. PubMed ID: 21762083
[TBL] [Abstract][Full Text] [Related]
18. Kinome profiling analysis identified Src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma.
Jimura N; Fujii K; Qiao Z; Tsuchiya R; Yoshimatsu Y; Kondo T; Kanekura T
J Dermatol Sci; 2021 Mar; 101(3):194-201. PubMed ID: 33531202
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphoma.
Wells CE; Bhaskara S; Stengel KR; Zhao Y; Sirbu B; Chagot B; Cortez D; Khabele D; Chazin WJ; Cooper A; Jacques V; Rusche J; Eischen CM; McGirt LY; Hiebert SW
PLoS One; 2013; 8(7):e68915. PubMed ID: 23894374
[TBL] [Abstract][Full Text] [Related]
20. Mechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell Lymphoma.
Mishra A; La Perle K; Kwiatkowski S; Sullivan LA; Sams GH; Johns J; Curphey DP; Wen J; McConnell K; Qi J; Wong H; Russo G; Zhang J; Marcucci G; Bradner JE; Porcu P; Caligiuri MA
Cancer Discov; 2016 Sep; 6(9):986-1005. PubMed ID: 27422033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
